Tauopathy

Summary

Tauopathy (MONDO:0005574) is a disease and 24 clinical trials. Top therapeutic interventions include flortaucipir, donanemab, and florbetaben f18. A subtype of neurodegenerative disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 24

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tauopathy
Mondo ID	MONDO:0005574
EFO	EFO:0005815
MeSH	D024801
DOID	DOID:680
UMLS	C0949664
MedGen	181880
Is cancer (heuristic)	no

Disease family

This is a subtype of neurodegenerative disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › neurodegenerative disease › tauopathy

Related subtypes (21): synucleinopathy, eyelid degenerative disorder, senile degeneration of brain, olivopontocerebellar atrophy, neuroaxonal dystrophy, demyelinating disease, choroidal sclerosis, secondary Parkinson disease, infantile bilateral striatal necrosis, Marchiafava-Bignami disease, superficial siderosis, primary progressive apraxia of speech, human prion disease, primary progressive freezing gait, primary progressive aphasia, motor neuron disorder, brachial amyotrophic diplegia, cerebellar degeneration, inherited neurodegenerative disorder, cerebral degeneration, hypertrophic olivary degeneration

Subtypes (2): Alzheimer disease, argyrophilic grain disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 24.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	11
PHASE2	5
PHASE1	3
EARLY_PHASE1	3
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05508789	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5)
NCT02676843	PHASE2	COMPLETED	Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
NCT03538522	PHASE2	COMPLETED	A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
NCT04445831	PHASE1/PHASE2	COMPLETED	A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer’s Disease
NCT05318976	PHASE2	COMPLETED	A Study of XPro1595 in Patients With Early Alzheimer’s Disease With Biomarkers of Inflammation
NCT05321498	PHASE2	WITHDRAWN	Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
NCT05522387	PHASE2	TERMINATED	An Open-Label Extension of XPro1595 in Patients With Alzheimer’s Disease
NCT02103894	PHASE1	COMPLETED	Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
NCT02294851	PHASE1	COMPLETED	A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects
NCT05344989	PHASE1	UNKNOWN	A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants
NCT06032026	EARLY_PHASE1	RECRUITING	Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
NCT06303921	EARLY_PHASE1	RECRUITING	Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
NCT06932809	EARLY_PHASE1	RECRUITING	Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
NCT06083467	Not specified	RECRUITING	CW2IP2: Imaging and Diagnostic Assessments
NCT06596746	Not specified	RECRUITING	Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
NCT06690983	Not specified	RECRUITING	Tau PET/CT in Various Tau-Related Disease Patients
NCT07306598	Not specified	RECRUITING	[18F]NIDF PET Imaging in Tau-related Diseases
NCT01696591	Not specified	UNKNOWN	The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD
NCT02860338	Not specified	COMPLETED	COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
NCT03938870	Not specified	COMPLETED	CNS Tau Kinetics in Healthy Aging and Alzheimer’s Disease
NCT05080777	Not specified	COMPLETED	Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
NCT05202223	Not specified	COMPLETED	Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers
NCT05427448	Not specified	COMPLETED	Validation of Blood Biomarkers for Alzheimer’s Disease
NCT05527288	Not specified	COMPLETED	A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLORTAUCIPIR	4	3
DONANEMAB	4	1
FLORBETABEN F18	4	1
LEUCINE	3	1
PEGIPANERMIN	2	3
GOSURANEMAB	2	1